Antibody variants and fragments thereof
CA 2323757 C · Owner: Idusogie, Esohe Ekinaduese · Inventors: Mulkerrin, Michael George; Presta, Leonard G.; Idusogie, Esohe Ekinaduese
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A variant of a polypetide comprising a human IgG Fc region is described which , variant comprises an amino acid substitution at one or more of amino acid positions 270, 322, 326, 327, 329, 331 333 or 334 of the human IgG Fc region. Such variants display altered effector function. For example C1q binding , and/or complement dependent cytotoxicity (CDC) activity may be altered in the variant polypeptide. The application also discloses a variant of a parent polypeptide comprising a human IgG Fc region which variant has a better , binding affinity for human C1q than the parent polypeptide.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 31, 1999 and granted August 2, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 31, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 31, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.